Suppr超能文献

2011 年至 2020 年间,接受常规治疗的巴西溃疡性结肠炎患者的肠道并发症。

Intestinal complications in Brazilian patients with ulcerative colitis treated with conventional therapy between 2011 and 2020.

机构信息

Espirito Santo Health Office, State Office for Pharmaceutical Assistance, Espirito Santos 29056-030, Brazil.

Department of Gastroenterology, Specialized Medical Center, Marília 17502-020, Brazil.

出版信息

World J Gastroenterol. 2023 Feb 28;29(8):1330-1343. doi: 10.3748/wjg.v29.i8.1330.

Abstract

BACKGROUND

This was an observational, descriptive, and retrospective study from 2011 to 2020 from the Department of Informatics of the Brazilian Healthcare System database.

AIM

To describe the intestinal complications (IC) of patients with ulcerative colitis (UC) who started conventional therapies in Brazil´s public Healthcare system.

METHODS

Patients ≥ 18 years of age who had at least one claim related to UC 10 revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) code and at least 2 claims for conventional therapies were included. IC was defined as at least one claim of: UC-related hospitalization, procedures code for rectum or intestinal surgeries, and/or associated disease defined by ICD-10 codes (malignant neoplasia of colon, stenosis, hemorrhage, ulcer and other rectum or anus disease, megacolon, functional diarrhea volvulus, intussusception and erythema nodosum). Descriptive statistics, annual incidence, and incidence rate (IR) [per 100 patient-years (PY)] over the available follow-up period were cal-culated.

RESULTS

In total, 41229 UC patients were included (median age, 48 years; 65% women) and the median (interquartile range) follow-up period was 3.3 (1.8-5.3) years. Conventional therapy used during follow-up period included: mesalazine (87%), sulfasalazine (15%), azathioprine (16%) or methotrexate (1%) with a median duration of 1.9 (0.8-4.0) years. Overall IR of IC was 3.2 cases per 100 PY. Among the IC claims, 54% were related to associated diseases, 20% to procedures and 26% to hospitalizations. The overall annual incidence of IC was 2.9%, 2.6% and 2.5% in the first, second and third year after the first claim for therapy (index date), respectively. Over the first 3 years, the annual IR of UC-related hospitalizations ranged from 0.8% to 1.1%; associated diseases from 0.9% to 1.2% - in which anus or rectum disease, and malignant neoplasia of colon were the most frequently reported; and procedure events from 0.6% to 0.7%, being intestinal resection and polyp removal the most frequent ones.

CONCLUSION

Study shows that UC patients under conventional therapy seem to present progression of disease developing some IC, which may have a negative impact on patients and the burden on the health system.

摘要

背景

这是一项 2011 年至 2020 年期间,来自巴西医疗保健系统数据库信息部门的观察性、描述性和回顾性研究。

目的

描述在巴西公共医疗保健系统中开始接受常规治疗的溃疡性结肠炎(UC)患者的肠道并发症(IC)。

方法

纳入年龄≥18 岁、至少有一次与 UC 相关的国际疾病分类第十次修订版(ICD-10)编码的索赔和至少两次常规治疗索赔的患者。IC 定义为至少有一次以下索赔之一:UC 相关住院治疗、直肠或肠道手术程序代码、和/或 ICD-10 代码定义的相关疾病(结肠恶性肿瘤、狭窄、出血、溃疡和其他直肠或肛门疾病、巨结肠、功能性腹泻、肠扭转、肠套叠和结节性红斑)。计算了可用随访期间的描述性统计数据、年度发病率和发病率(IR)[每 100 患者年(PY)]。

结果

共纳入 41229 例 UC 患者(中位年龄 48 岁,65%为女性),中位(四分位距)随访时间为 3.3(1.8-5.3)年。随访期间使用的常规治疗包括:美沙拉嗪(87%)、柳氮磺胺吡啶(15%)、硫唑嘌呤(16%)或甲氨蝶呤(1%),中位持续时间为 1.9(0.8-4.0)年。IC 的总体 IR 为每 100 PY 3.2 例。在 IC 索赔中,54%与相关疾病有关,20%与程序有关,26%与住院治疗有关。在首次治疗(索引日期)后的第 1、2 和第 3 年,IC 的总体年度发病率分别为 2.9%、2.6%和 2.5%。在最初的 3 年中,UC 相关住院治疗的年发病率范围为 0.8%至 1.1%;相关疾病为 0.9%至 1.2%,其中肛门或直肠疾病和结肠恶性肿瘤最为常见;手术事件为 0.6%至 0.7%,肠切除术和息肉切除术最为常见。

结论

研究表明,接受常规治疗的 UC 患者似乎出现了疾病进展,出现了一些 IC,这可能对患者和医疗系统的负担产生负面影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d725/10011965/9e6f18e79e94/WJG-29-1330-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验